A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise. / Paulsen, G; Egner, I M; Drange, M; Langberg, Henning; Benestad, H B; Fjeld, J G; Hallén, J; Raastad, T.
In: Scandinavian Journal of Medicine & Science in Sports, Vol. 20, No. 1, 2010, p. e195-207.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise
AU - Paulsen, G
AU - Egner, I M
AU - Drange, M
AU - Langberg, Henning
AU - Benestad, H B
AU - Fjeld, J G
AU - Hallén, J
AU - Raastad, T
PY - 2010
Y1 - 2010
N2 - The aim of this study was to investigate the effect of a cyclooxygenase (COX)-2 inhibitor on the recovery of muscle function, inflammation, regeneration after, and adaptation to, unaccustomed eccentric exercise. Thirty-three young males and females participated in a double-blind, placebo-controlled experiment. Seventy unilateral, voluntary, maximal eccentric actions with the elbow flexors were performed twice (bouts 1 and 2) with the same arm, separated by 3 weeks. The test group participants were administered 400 mg/day of celecoxib for 9 days after bout 1. After both bouts 1 and 2, concentric and isometric force-generating capacity was immediately reduced (approximately 40-50%), followed by the later appearance of muscle soreness and increased serum creatine kinase levels. Radiolabelled autologous leukocytes (detected by scintigraphy) and monocytes/macrophages (histology) accumulated in the exercised muscles, simultaneously with increased satellite cell activity. These responses were reduced and recovery was faster after bout 2 than 1, demonstrating a repeated-bout effect. No differences between the celecoxib and placebo groups were detected, except for muscle soreness, which was attenuated by celecoxib. In summary, celecoxib, a COX-2 inhibitor, did not detectably affect recovery of muscle function or markers of inflammation and regeneration after unaccustomed eccentric exercise, nor did the drug influence the repeated-bout effect. However, it alleviated muscle soreness.
AB - The aim of this study was to investigate the effect of a cyclooxygenase (COX)-2 inhibitor on the recovery of muscle function, inflammation, regeneration after, and adaptation to, unaccustomed eccentric exercise. Thirty-three young males and females participated in a double-blind, placebo-controlled experiment. Seventy unilateral, voluntary, maximal eccentric actions with the elbow flexors were performed twice (bouts 1 and 2) with the same arm, separated by 3 weeks. The test group participants were administered 400 mg/day of celecoxib for 9 days after bout 1. After both bouts 1 and 2, concentric and isometric force-generating capacity was immediately reduced (approximately 40-50%), followed by the later appearance of muscle soreness and increased serum creatine kinase levels. Radiolabelled autologous leukocytes (detected by scintigraphy) and monocytes/macrophages (histology) accumulated in the exercised muscles, simultaneously with increased satellite cell activity. These responses were reduced and recovery was faster after bout 2 than 1, demonstrating a repeated-bout effect. No differences between the celecoxib and placebo groups were detected, except for muscle soreness, which was attenuated by celecoxib. In summary, celecoxib, a COX-2 inhibitor, did not detectably affect recovery of muscle function or markers of inflammation and regeneration after unaccustomed eccentric exercise, nor did the drug influence the repeated-bout effect. However, it alleviated muscle soreness.
KW - Adaptation, Physiological
KW - Adult
KW - Arm
KW - Cyclooxygenase 2 Inhibitors
KW - Dinoprostone
KW - Double-Blind Method
KW - Exercise
KW - Female
KW - Humans
KW - Immunohistochemistry
KW - Isometric Contraction
KW - Leukocytes
KW - Male
KW - Microdialysis
KW - Muscle Contraction
KW - Muscle, Skeletal
KW - Pain
KW - Pyrazoles
KW - Recovery of Function
KW - Satellite Cells, Skeletal Muscle
KW - Sulfonamides
KW - Young Adult
U2 - 10.1111/j.1600-0838.2009.00947.x
DO - 10.1111/j.1600-0838.2009.00947.x
M3 - Journal article
C2 - 19522751
VL - 20
SP - e195-207
JO - Scandinavian Journal of Medicine & Science in Sports
JF - Scandinavian Journal of Medicine & Science in Sports
SN - 0905-7188
IS - 1
ER -
ID: 38364620